Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Mar:108:105405.
doi: 10.1016/j.meegid.2023.105405. Epub 2023 Jan 18.

Global SARS-CoV-2 genomic surveillance: What we have learned (so far)

Affiliations
Review

Global SARS-CoV-2 genomic surveillance: What we have learned (so far)

Stephane Tosta et al. Infect Genet Evol. 2023 Mar.

Abstract

The COVID-19 pandemic has brought significant challenges for genomic surveillance strategies in public health systems worldwide. During the past thirty-four months, many countries faced several epidemic waves of SARS-CoV-2 infections, driven mainly by the emergence and spread of novel variants. In that line, genomic surveillance has been a crucial toolkit to study the real-time SARS-CoV-2 evolution, for the assessment and optimization of novel diagnostic assays, and to improve the efficacy of existing vaccines. During the pandemic, the identification of emerging lineages carrying lineage-specific mutations (particularly those in the Receptor Binding domain) showed how these mutations might significantly impact viral transmissibility, protection from reinfection and vaccination. So far, an unprecedented number of SARS-CoV-2 viral genomes has been released in public databases (i.e., GISAID, and NCBI), achieving 14 million genome sequences available as of early-November 2022. In the present review, we summarise the global landscape of SARS-CoV-2 during the first thirty-four months of viral circulation and evolution. It demonstrates the urgency and importance of sustained investment in genomic surveillance strategies to timely identify the emergence of any potential viral pathogen or associated variants, which in turn is key to epidemic and pandemic preparedness.

Keywords: Epidemic-pandemic preparedness; Genomic surveillance; SARS-CoV-2; Viral evolution.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest Not declared.

Figures

Fig. 1
Fig. 1
Timeline of the progression and milestones occurring during the COVID-19 pandemic (December 2019–October 2022). The first COVID-19 case reported is illustrated in blue, the number of reported COVID-19 cases milestones are illustrated in yellow, the total deaths milestones are illustrated in red, the detection of VOCs are illustrated in green. The ring colour indicates different years (2019–2022), as reported in the legend on the top left. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Fig. 2
Fig. 2
Genomic surveillance framework for the real-time monitoring of emerging and re-emerging viral pathogens. The framework will include 6 steps. The first step will focus on sample collection. In the second step, outbreak isolates are submitted to molecular screening using real-time PCR. Next (iii), positive samples will be submitted to whole genome sequences and subsequently assembled either using de novo or mapped against a reference genome strategy. Next (iv), novel strains will be submitted to phylogenetic and phylodynamic inferences which in turn will make possible the identification of potential genomic differences through the analysis of the mutational pattern profile (v). In the final step (vi), genomic data will be analysed together with epidemiological, clinical, climatic and mobility data for greatly facilitating large-scale genomic epidemiological investigations.
Fig. 3
Fig. 3
VOCs world distribution according to their sequenced genomes. The legend on the bottom right indicates the progression and the spread of each VOC through time at the countrywise level.
Fig. 4
Fig. 4
Zoonotic transmission chains. Interactions between humans, and different host species (including wild, domestic animals and vectors), which are important drivers for spillover and spillback events. Different colours indicates different epidemic waves.

Similar articles

Cited by

References

    1. Alcantara L.C.J., Nogueira E., Shuab G., Tosta S., Fristch H., Pimentel V., Souza-Neto J.A., Coutinho L.L., Fukumasu H., Sampaio S.C., Elias M.C., Kashima S., Slavov S.N., Ciccozzi M., Cella E., Lourenco J., Fonseca V., Giovanetti M. SARS-CoV-2 epidemic in Brazil: how the displacement of variants has driven distinct epidemic waves. Virus Res. 2022;2(315):198–785. doi: 10.1016/j.virusres.2022.198785. - DOI - PMC - PubMed
    1. Andrews N., Stowe J., Kirsebom F., Toffa S., Sachdeva R., Gower C., Ramsay M., Lopez Bernal J. Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England. Nat. Med. 2022;28(4) doi: 10.1038/s41591-022-01699-1. Article 4. - DOI - PMC - PubMed
    1. Barouch, D. H. (2022). Covid-19 VaccinesBashor, L. Gagne, R. B. Bosco-Lauth, A. M. Bowen, R. A. Stenglein, VandeWoude, M. S. (2021) SARS-CoV-2 evolution in animals suggests mechanisms for rapid variant selection. Proc. Natl. Acad. Sci., 118(44), e2105253118. doi:10.1073/pnas.2105253118. - DOI - PMC - PubMed
    1. Barrett A.D.T., Titball R.W., MacAry P.A., Rupp R.E., von Messling V., Walker D.H., Fanget N.V.J. The rapid progress in COVID vaccine development and implementation. Npj Vaccines. 2022;7(1) doi: 10.1038/s41541-022-00442-8. Article 1. - DOI - PMC - PubMed
    1. Bedford J., Enria D., Giesecke J., Heymann D.L., Ihekweazu C., Kobinger G., Lane H.C., Memish Z., Oh M., Sall A.A., Schuchat A., Ungchusak K., Wieler L.H. COVID-19: towards controlling a pandemic. Lancet. 2020;395(10229):1015–1018. doi: 10.1016/S0140-6736(20)30673-5. - DOI - PMC - PubMed

Publication types